The objective of the group will be to investigate the formation, maintenance and consequences of extrachromosomal DNA (ecDNA) in cancer using cutting edge single-cell screening and spatial technologies. ecDNA leads to high amplification of oncogenes or genes involved in drug resistance under selective pressures and has a prominent role in cancer heterogeneity. The overarching goal will be to identify druggable targets that reduce ecDNA abundance in cancer – and hence ablating a potent tool of genetic heterogeneity and a powerhorse of drug resistance in cancer.
- Dr. Ralph Lindemann
Global Head, Translational & Biomarker Research, TIP Oncology & Immunooncology, Merck, Darmstadt, Germany (Industry mentor)
- Dr. Sebastian M. Waszak
Group Leader, Computational Oncology Group, Centre for Molecular Medicine Norway (NCMM), University of Oslo & Associate Professor, Neurology, University of California, San Francisco (Academic mentor)